GlycoMimetics Inc. - GLYC Quarterly EPS earnings growth

Corporate company logo of GlycoMimetics Inc. (GLYC)

GlycoMimetics, Inc. (GLYC) management is striving to eliminate uplizusan test delays while ensuring pipeline transparency. The quarterly EPS growth rate clearly demonstrates this trend, with the latest parameter standing at 78.30. Drug safety is guaranteed through strict adherence to the cold chain during delivery. The company is currently in a strict cost-cutting mode, seeking emergency merger options following failed trials.

glycomimetics.com (GLYC) Year-over-year earnings per one share growth for the last 12 months: for the period 07/04/2022 - 06/16/2025

Analytical breakdowns for GlycoMimetics, Inc.

- share price and consensus valuation forecast:
Stock Quotes glycomimetics.com|GLYC - Analyst Forecast Prices
- issuer market value details:
Market Capitalization GlycoMimetics Corp|GLYC - Enterprise Value
- balance sheet net asset value indicators:
Net Assets per Single Share GlycoMimetics|GLYC - Accounting Value of Company|Market Capitalization to Book Value Ratio glycomimetics.com|GLYC - Company Balance Sheet Assets
- debt and liquidity data:
Total Debt to Capital GlycoMimetics, Inc.|GLYC - Long-Term Liabilities to Capital|Short-Term Debt to Equity Ratio glycomimetics.com|GLYC - Company Cumulative Indebtedness|Debts to Book Capitalization GlycoMimetics Corp|GLYC - Long-Term Debt|Company Short-Term Debts GlycoMimetics|Quick Liquidity Indicator glycomimetics.com
- earnings and market multiples details:
GLYC - Final Profit|Future Profit GlycoMimetics, Inc.|GLYC - Market Price to Net Income Ratio|Forward P/E Multiple glycomimetics.com|GLYC - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple GlycoMimetics Corp|GLYC - Profit before interest, taxes and amortization|Earnings per share for the last twelve months GlycoMimetics|GLYC - Earnings per share for the trailing year|Quarterly EPS earnings growth glycomimetics.com|GLYC - Earnings growth in current year|Net earnings per share growth forecast for next year GlycoMimetics, Inc.
- sales revenue and business income indicators:
GLYC - Company Annual Revenue|Company Future Sales Volume glycomimetics.com|GLYC - Price to Sales|Forward P/S Multiple GlycoMimetics Corp
Fundamental company valuation:GlycoMimetics Inc. - GLYC
Flagship merchandise of GlycoMimetics

This metric measures the quarterly dynamics of net earnings per share, allowing for an assessment of capital management efficiency and business scaling rates. By analyzing the quarterly change in earnings per share, an investor can correlate the financial results of GlycoMimetics, Inc. (GLYC) with R&D expenditures and patent protection, identifying the company's resilience to the risks associated with prolonged clinical trials.

Analysis of competing companies

GMAB (Genmab) - Year-over-year net earnings per share growth for the last 12 months|EXEL: Year-over-year earnings per share growth rate for the last twelve months|NUVL (Nuvalent Corp) - Quarterly EPS earnings growth|Quarterly EPS earnings growth Kymera Corp|Year-over-year earnings per share growth for the last twelve months IDEAYA Biosciences (IDYA)|ELVN (enliventherapeutics.com) - Year-over-year earnings per one share growth for the last 12 months|Quarterly EPS earnings growth ORIC (ORIC Pharmaceuticals, Inc.)|Net earnings per share growth for the trailing year Relay Therapeutics Inc|Nurix Pharma - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Tyra Corp|VSTM (Verastem, Inc.) - Year-over-year net earnings per share growth for the last 12 months|GLUE: Year-over-year earnings per share growth rate for the last twelve months|CGEM (Cullinan Therapeutics, Inc.) - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Immuneering Corp IMRX|Quarterly EPS earnings growth CCCC|Black Diamond Therapeutics, Inc - Year-over-year earnings per share growth for the last 12 months|Repare Therapeutics - Year-over-year net earnings per share growth for the last 12 months|Year-over-year earnings per one share growth for the last 12 months PMVP|KPTI: Year-over-year net earnings per share growth for the last 12 months|Propanc Biopharma Inc - Year-over-year earnings per share growth rate for the last twelve months|BGMS: Quarterly EPS earnings growth|Aadi Bioscience, Inc. - Year-over-year earnings per one share growth for the last 12 months|ALRN (Aileron Therapeutics Inc) - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Blueprint Medicines Corp BPMC|Year-over-year earnings per share growth for the last twelve months SpringWorks Therapeutics, Inc. (SWTX)